pharmaceuticals
pharmaceuticals Articles
Proteostasis Therapeutics has registered an S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Chimerix absolutely led the bears in Monday’s trading session on less-than-favorable results from a late-stage trial.
Published:
Last Updated:
These companies all provide drugs and medical devices that help hundreds of thousands of people daily lead a better life. They make good sense for conservative portfolios looking for income and...
Published:
Last Updated:
While there is certainly no guarantee that any of these hot biotech companies is bought, they each offer aggressive accounts big potential upside and have unique products and clinical possibilities...
Published:
Last Updated:
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
Published:
Last Updated:
Biotech gets a lot of sustained attention, but some stocks still fall through the cracks, either due to recent failures or general lack of interest.
Published:
Last Updated:
Good news for those who suffer from high levels of uric acid and from gout: the FDA has approved a new gout treatment.
Published:
Last Updated:
pSivida was leading the bulls in Tuesday’s session on positive results from a late stage trial of Medidur.
Published:
Last Updated:
AVEO Pharmaceuticals was leading the bulls in Monday’s session on news of an exclusive licensing agreement.
Published:
Last Updated:
Collegium Pharmaceutical has filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.
Published:
Last Updated:
KemPharm expects to price its 3 million shares around last Thursday's closing price of $18.88, which would value the entire secondary offering at up to more than $65 million.
Published:
Last Updated:
Intercept Pharmaceuticals announced that the FDA has extended the PDUFA date for its Priority Review of obeticholic acid in primary biliary cholangitis.
Published:
Last Updated:
Advaxis has announced that the FDA has lifted the clinical hold on all of its Investigational New Drug (IND) applications for its three product candidates
Published:
Last Updated:
Array BioPharma reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial.
Published:
Last Updated:
Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a Big Pharma stock.
Published:
Last Updated: